Press

Sunstone Therapies Announces Expansion of Innovative Dyad Study

Oct 3 • 3 min read

Sunstone Therapies Announces Expansion of Innovative Dyad Study Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development and execution of clinical trials, today announces the expansion of its MDMA-assisted Dyad Study to include 20 dyads (pairs of participants). The study is being funded in part from a significant grant by…

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

Oct 3 • 4 min read

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is proud to introduce its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. Operating out of the Numinus Wellness UT and Cedar Clinical…

Disposition of Common Shares of Small Pharma Inc.

Oct 3 • 2 min read

Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “Company”) between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proceeds of $284,199.177. Prior to the disposition, and as at the date of his last early…

Jupiter Acquisition Files Investor Presentation on Filament Health Deal

Oct 3 • 1 min read

Jupiter Acquisition in a regulatory filing included an investor presentation promoting its proposed merger with Filament Health, a Canadian clinical‐stage psychedelic drug development company. The combination had a pro forma enterprise value of about $210 million at deal announcement in July. The deal is expected to provide at least $5 million of net proceeds to the combined company….

Atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Oct 2 • 3 min read

Atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the completion of the Phase 1 study of VLS-01 in healthy participants. “We are pleased to report the completion of the Phase 1 study of VLS-01, in which we demonstrated a supportive PK/PD profile of our proprietary…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435